Tuesday, Nov 12 2019 | Time 16:19 Hrs(IST)
image
  • Putin not against meeting with Zelenskyy, but preparations needed - Kremlin
  • Kamal will meet same fate as Sivaji in politics : Palaniswami
  • Governor recommends President's rule in Maharashtra
  • Normal rail traffic restored on Kacheguda Rly station
  • Shiv Sena likely to approach SC against Guv's decision
  • DRI seizes 50 lakh foreign cigarettes worth Rs 7 cr at Chennai Port
  • In the line of duty
  • HADR Exercise to commence at Vizag from Nov 13
  • Father of Assange receives no offer of compensation from UK, Sweden
  • Hong Kong: School, varsities remain shut; agitators struck transport
  • JDS' opinion towards BJP changed after falling of their alliance with Cong: Siddaramaiah
  • Kyrgyzstan ratifies Paris Climate Agreement - Presidential Office
  • UNION CABINET RECOMMENDS PRESIDENT'S RULE IN MAHARASHTRA
  • PM leaves for Brazil to attend BRICS Summit
  • Father of WikiLeaks founder Julian Assange says his son's health is in poor condition
Science Technology


WHO revises recommendations on hormonal contraceptive use for women at high HIV risk

WHO revises recommendations on hormonal contraceptive use for women at high HIV risk

Kolkata, Aug 30 (UNI) The World Health Organization (WHO) has revised its guidance on

contraceptive use to reflect new evidence that women at high risk of HIV can use any form

of reversible contraception, including progestogen-only injectables, implants and intrauterine

devices (IUDs), without an increased risk of HIV infection.

However, as these contraceptive methods do not protect against HIV and other sexually

transmitted infections (STIs), the guideline emphasizes that correct and consistent use of

condoms should be used where there is a risk of STIs, including HIV, a WHO media

statement here on Friday said.

WHO also recommends considering offering pre-exposure prophylaxis (PrEP) in settings

where the incidence of HIV is above 3 per cent, as appropriate.

The updated WHO guideline follows a thorough review of the latest scientific evidence.

It emphasizes that women should have access to the full range of modern contraceptive

methods so they can make informed choices around contraceptive choice and their sexual

health.

“Evidence shows that a woman’s risk of HIV should not restrict her contraceptive choice,”

said Dr Peter Salama, Executive Director, Universal Health Coverage/Life Course at WHO.

“All women should have access to a wide range of options for contraception as well as to

HIV prevention and to treatment if needed.”

The updated recommendations to the WHO guideline, Medical eligibility criteria for

contraceptive use, stem from a review of the latest evidence conducted by the independent

Guideline Development Group convened to inform WHO.

This Group assessed all of the evidence on hormonal contraception and risk of HIV

acquisition published since the previous review published in 2016, along with a systematic

review of all published evidence on copper-bearing IUDs and HIV risk.

The new evidence is largely based on the results of the Evidence for Contraceptive

Options and HIV Outcomes (or ECHO trial) - a randomized clinical trial that showed no

statistically significant differences in HIV acquisition among women using intramuscular

depot medroxyprogesterone acetate (DMPA-IM), copper IUDs, or levonorgestrel (LNG)

implants.

This new high-quality evidence supersedes the low to low-moderate quality evidence

from observational studies that had been previously available to inform WHO’s guidance.

The ECHO study – which was conducted across communities expected to have high

levels of HIV prevalence in Eswatini, Kenya, South Africa and Zambia - also revealed

concerningly high levels of HIV acquisition and other sexually transmitted infections (STIs)

among women seeking contraceptive services, particularly younger women, irrespective

of which of the three contraceptive methods they used.

“There is a clear need to ensure women in Africa have access to high quality HIV and

STI prevention and testing services, along with a wide range of contraceptive options to

suit their values, preferences, views and concerns,” said Dr Felicitas Zawaira, Director of

Family and Reproductive Health in WHO’s African region.

“In high HIV prevalence settings, these may include condom promotion, pre-exposure

prophylaxis (PrEP), as well as linkages to antiretroviral therapy for those testing HIV-positive,

and partner testing.”

MORE UNI BM SJC

More News
Max number of breast cancer patients in India are in 40-60 age group: Expert

Max number of breast cancer patients in India are in 40-60 age group: Expert

31 Oct 2019 | 4:01 PM

New Delhi, Oct 31 (UNI) The maximum number of patients diagnosed with breast cancer in India are in the age group of 40-60 years, says a health expert.

see more..
Guidelines for evaluation of Nanopharmaceuticals in India released

Guidelines for evaluation of Nanopharmaceuticals in India released

24 Oct 2019 | 9:37 PM

New Delhi, Oct 24 (UNI) Union Minister for Science and Technology Dr Harsh Vardhan on Thursday said that “Guidelines for Evaluation of Nanopharmaceuticals in India” is one of the most important steps for delineating quality, safety and efficacy assessment of the novel nano-formulations.

see more..
Scientists discover how to detect precancerous conditions with nanodiamonds

Scientists discover how to detect precancerous conditions with nanodiamonds

10 Oct 2019 | 12:30 PM

New Delhi, Oct 10 (UNI) Scientists have been actively exploring Detonation nanodiamonds' (DNDs) interaction with biological structures and biomacromolecules and now, the findings are being used to treat tumours, as well as to develop biosensors and biocompatible implants.

see more..
SGRH completes 1000 Vascular Surgery cases in Artis Q Hybrid OR

SGRH completes 1000 Vascular Surgery cases in Artis Q Hybrid OR

04 Oct 2019 | 9:37 PM

New Delhi, Oct 4 (UNI) The Institute of vascular and endovascular sciences at Sir Ganga Ram Hospital (SGRH) has successfully completed 1000 cases of vascular surgery in Artis Q Hybrid OR.

see more..
Charting the 'Generic' terrain for future

Charting the 'Generic' terrain for future

26 Sep 2019 | 3:19 PM

By Rishira Jain
New Delhi, Sep 26 (UNI) For India to grow, healthcare, as the engine of the economy, needs to flourish and to make the affordable medication a reality, generic drugs is the only charted terrain in the country that can ensure affordable access to healthcare and the future sustainability of medicines development.

see more..
image